Staging of pancreatic cancer based on the number of positive lymph nodes. BJS 2017; 104: 608-618.
Published: 14th February 2017
Authors: I. Tarantino, R. Warschkow, T. Hackert, B. M. Schmied, M. W. Büchler, O. Strobel et al.
The International Study Group on Pancreatic Surgery has stated that at least 12 lymph nodes should be evaluated for staging of pancreatic cancer. The aim of this population‐based study was to evaluate whether the number of positive lymph nodes refines staging.
Patients who underwent pancreatectomy for stage I–
Some 5036 patients were included, with a median of 18 (i.q.r. 15–24) lymph nodes examined. Positive lymph nodes were found in 3555 patients (70·6 per cent). The median duration of follow‐up was 15 (i.q.r. 8–28) months.
The number of positive lymph nodes in the resection specimen is a prognostic factor in patients with pancreatic cancer.Read more
You may also be interested in
Authors: R. Ahola, A. Siiki, K. Vasama, M. Vornanen, J. Sand, J. Laukkarinen et al.
Notes: Centralization influences long‐term survival
Systematic review of transarterial embolization for hepatocellular adenomas. BJS 2017; 104: 823-835.
Authors: B. V. van Rosmalen, R. J. S. Coelen, M. Bieze, O. M. van Delden, J. Verheij, C. H. C. Dejong et al.
Notes: Safe alternative to surgery
Meta‐analysis of adjuvant therapy following curative surgery for periampullary adenocarcinoma. BJS 2017; 104: 814-822.
Authors: A. Acharya, S. R. Markar, M. H. Sodergren, G. Malietzis, A. Darzi, T. Athanasiou et al.
Notes: No benefit
Authors: T. Ebata, T. Mizuno, Y. Yokoyama, T. Igami, G. Sugawara, M. Nagino et al.
Notes: irresectability revisited
Survival benefit of liver resection for Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma. BJS 2017; 104: 1045-1052.
Authors: H. Kim, S. W. Ahn, S. K. Hong, K. C. Yoon, H.‐S. Kim, Y. R. Choi et al.
Notes: Selected patients benefit
Accuracy of circulating histones in predicting persistent organ failure and mortality in patients with acute pancreatitis.
Authors: T. Liu, W. Huang, P. Szatmary, S. T. Abrams, Y. Alhamdi, Z. Lin et al.
Notes: Potential as early prediction biomarker
Dual hypothermic oxygenated machine perfusion in liver transplants donated after circulatory death. BJS 2017; 104: 907-917.
Authors: R. van Rijn, N. Karimian, A. P. M. Matton, L. C. Burlage, A. C. Westerkamp, A. P. van den Berg et al.
Notes: Increases donor pool
Prospective trial to evaluate the prognostic value of different nutritional assessment scores in pancreatic surgery (NURIMAS Pancreas). BJS 2017; 104: 1053-1062.
Authors: P. Probst, S. Haller, T. Bruckner, A. Ulrich, O. Strobel, T. Hackert et al.
Notes: No score of use
Authors: F. J. Hüttner, P. Probst, P. Knebel, O. Strobel, T. Hackert, A. Ulrich et al.
Notes: No benefit
Prognostic impact of margin status in liver resections for colorectal metastases after bevacizumab. BJS 2017; 104: 926-935.
Authors: K. Sasaki, G. A. Margonis, N. Andreatos, A. Wilson, M. Weiss, C. Wolfgang et al.
Notes: Antiangiogenesis antibody of benefit
Impact of hepatobiliary service centralization on treatment and outcomes in patients with colorectal cancer and liver metastases. BJS 2017; 104: 918-925.
Authors: A. E. Vallance, J. vanderMeulen, A. Kuryba, I. D. Botterill, J. Hill, D. G. Jayne et al.
Notes: Better survival
Liver transection using indocyanine green fluorescence imaging and hepatic vein clamping. BJS 2017; 104: 898-906.
Authors: Y. Kawaguchi, Y. Nomura, M. Nagai, D. Koike, Y. Sakuraoka, T. Ishida et al.
Notes: To see or not to see